HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PNTG

The Pennant Group, Inc. (NASDAQ)

Healthcare — Medical Care Facilities

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities in Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The Company was incorporated in 2019 and is headquartered in Eagle, Idaho.

Strong Buy 1.1 / 5 6 analysts
$37.36
+$0.41 (+1.11%)
Target: $40.83 (9.3%)
Sign in to add PNTG to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.30B
P/E Ratio (TTM)43.44
Forward P/E23.48
EPS (TTM)$0.86
Dividend Yield-
Profit Margin2.96%
Revenue Growth36.00%
ROE9.98%
Debt/Equity116.62
Recommendation Strong Buy 1.1
Analyst Target$40.83
Analysts6
Indexes NASDAQ

Technical Indicators

RSI (14)84.5
Beta1.27
SMA 20-
SMA 40-
52-Week High$38.54
52-Week Low$21.73
50-Day Avg$33.31
200-Day Avg$29.74
Avg Volume266.6K
Volume416.3K

Performance Analysis

NEUTRAL

PNTG presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($38.54), which may indicate limited upside.
- RSI at 84.5 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 43.4 is elevated — the market expects high growth or it may be overvalued.
+ Strong revenue growth of 36.0% year-over-year.
+ Wall Street consensus is "Strong Buy" from 6 analysts.
+ Average analyst target of $40.83 implies 9.3% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:27 UTC

Back to Screener Export Report